Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025

Core Viewpoint - Milestone Pharmaceuticals is preparing for the commercial launch of its lead investigational product, etripamil nasal spray (proposed trade name CARDAMYST™), aimed at managing paroxysmal supraventricular tachycardia (PSVT) with a launch expected in mid-2025 [2][4]. Group 1: Company Overview - Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing innovative cardiovascular solutions to improve the lives of patients with complex heart conditions [5]. - The company emphasizes understanding unmet patient needs and enhancing the patient experience through new treatment approaches that allow for self-management [5]. Group 2: Product Details - Etripamil is a novel calcium channel blocker nasal spray designed for self-administration, targeting symptomatic episodes of PSVT and atrial fibrillation with rapid ventricular rate (AFib-RVR) [4]. - The product is currently under review by the U.S. Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target date of March 27, 2025 [2]. - Etripamil aims to provide healthcare providers with a new treatment option for on-demand care and patient self-management, potentially enhancing patients' control over their condition [4]. Group 3: Upcoming Event - Milestone Pharmaceuticals will host an investor event on February 25, 2025, in New York, featuring presentations from the CEO and Chief Commercial Officer, detailing the commercial strategy for etripamil [1][2]. - A live question and answer session will follow the formal presentation, allowing for direct engagement with investors [3].